LY-3561774 is under clinical development by Dicerna Pharmaceuticals and currently in Phase II for Mixed Dyslipidemia. According to GlobalData, Phase II drugs for Mixed Dyslipidemia have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LY-3561774’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LY-3561774 is under development for the treatment of cardiometabolic diseases. The drug candidate is administered through subcutaneous route. The drug candidate is developed based on GalXC RNAi technology platform. It acts by targeting angiopoietin like protein 3 (ANGPTL3).
Dicerna Pharmaceuticals overview
Dicerna Pharmaceuticals (Dicerna) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of rare inherited diseases and cancers. The company’s lead product DCR-PHXC is used for the treatment of primary hyperoxaluria (PH). It offers RNAi technology platform GalXCTM is an advanced next-generation RNAi-based therapies that is designed to silence disease-driving genes in the liver. Dicerna’s GalXC-based therapies are processed by the Dicer enzyme, which is the natural initiation point for RNAi within the human cell. The company also develops therapies to treat diseases linking the liver includes rare, viral infections, chronic liver, and cardiovascular diseases. Dicerna is headquartered in Lexington, Massachusetts, the US.
For a complete picture of LY-3561774’s drug-specific PTSR and LoA scores, buy the report here.